<SEC-DOCUMENT>0001493152-25-011680.txt : 20250807
<SEC-HEADER>0001493152-25-011680.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807083008
ACCESSION NUMBER:		0001493152-25-011680
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250804
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39531
		FILM NUMBER:		251191786

	BUSINESS ADDRESS:	
		STREET 1:		601 21ST STREET, SUITE 300
		CITY:			VERO BEACH
		STATE:			FL
		ZIP:			32960
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		601 21ST STREET, SUITE 300
		CITY:			VERO BEACH
		STATE:			FL
		ZIP:			32960

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:PCSA="http://processapharmaceuticals.com/20250804">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_PCSA_processapharmaceuticals.com_20250804 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20250804_20250804 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001533743 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000004" name="dei:EntityCentralIndexKey">0001533743</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pcsa-20250804.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-04</xbrli:startDate>
        <xbrli:endDate>2025-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; text-transform: uppercase"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20250804__20250804_zT9gdKxH96x8"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20250804__20250804_zLySyCvtIUu2"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 4, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number <span style="background-color: white"><span id="xdx_906_edei--EntityFileNumber_c20250804__20250804_zI9SdpFD1G1c"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000011" name="dei:EntityFileNumber">001-39531</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20250804__20250804_zEN5phj3L4G5"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000012" name="dei:EntityRegistrantName">PROCESSA
PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as Specified in its Charter)</b></span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20250804__20250804_zUartj6DYpzi"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
  <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
  <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20250804__20250804_ziTvrS0E6dec"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000014" name="dei:EntityTaxIdentificationNumber">45-1539785</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                 or Other Jurisdiction of</b></span></p>
                                                                                <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>
                                 <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation
                                 or Organization)</b></span></p></td>
  <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
  <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification Number)</b></span></p></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250804__20250804_zUHPo1G78x86"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000015" name="dei:EntityAddressAddressLine1">601
21<sup>st</sup> Street</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20250804__20250804_zaR3MKXOvRl5"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
300</ix:nonNumeric></span></b></span><b> <span id="xdx_900_edei--EntityAddressCityOrTown_c20250804__20250804_zEvdZijq4zWg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000017" name="dei:EntityAddressCityOrTown">Vero
Beach</ix:nonNumeric></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250804__20250804_z3MgmjuVdMCd"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000018" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></span></b><b>
<span id="xdx_90C_edei--EntityAddressPostalZipCode_c20250804__20250804_zSU8p1TNyhaf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000019" name="dei:EntityAddressPostalZipCode">32960</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of Principal Executive Offices, Including Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--CityAreaCode_c20250804__20250804_zr5jzIelCA83"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000020" name="dei:CityAreaCode">(772)</ix:nonNumeric></span>
    <span id="xdx_900_edei--LocalPhoneNumber_c20250804__20250804_z4ucSsa0Ahqd"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000021" name="dei:LocalPhoneNumber">453-2899</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
Telephone Number, Including Area Code)</b></span></p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--WrittenCommunications_c20250804__20250804_zRNYrdNamMO"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--SolicitingMaterial_c20250804__20250804_z1QECskOW58a"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--PreCommencementTenderOffer_c20250804__20250804_zuaqZUJ3izs4"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20250804__20250804_z7VUi4uTWB5h"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20250804__20250804_zJBvBoaHx5ll"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000026" name="dei:Security12bTitle">Common
    stock: Par value $.0001</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20250804__20250804_z1G2kwHdIUY8"><ix:nonNumeric contextRef="AsOf2025-08-04" id="Fact000027" name="dei:TradingSymbol">PCSA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--SecurityExchangeName_c20250804__20250804_zOH2IFJ5vHDe"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20250804__20250804_zmoKBoz164Bl"><ix:nonNumeric contextRef="AsOf2025-08-04" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 4, 2025, <span style="background-color: white">Processa Pharmaceuticals, Inc. (the &#8220;Company&#8221;) </span>entered into
securities purchase agreements (the &#8220;Securities Purchase Agreement&#8221;) for a private placement with an accredited investor
wherein the Company sold 5,467,181 restricted shares of common stock at a purchase price of $0.23 per share for approximately $1.3 million
in gross proceeds (the &#8220;Offering&#8221;), before deducting Placement Agent fees and other expenses related to the Offering. The
Company intends to use the net cash proceeds from the Offering for general corporate purposes. The Offering closed on August 6, 2025.
In connection with this investment, we are evaluating corporate cryptocurrency treasury strategies as part of our broader financial
and growth objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Capital LLC (the &#8220;Placement Agent&#8221;) <span style="background-color: white">acted as the Company&#8217;s exclusive placement
agent in the Offering. The Company has agreed to pay the Placement Agent </span>a cash fee equal to 7.0% of the gross proceeds raised
in the Offering. The Company has also agreed to reimburse the Placement Agent for reasonable out-of-pocket expenses incurred in connection
with the Offering, as well as a maximum $150,000 in legal expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering is exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) pursuant
to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule
506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. The Purchaser represented
that it is an accredited investor within the meaning of Rule 501(a) of Regulation D, and was acquiring the securities for investment
only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered
without any general solicitation by the Company or its representatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 61.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
foregoing summary of the terms of the Securities Purchase Agreement is subject to, and qualified in their entirety by, such document
attached hereto as Exhibit 10.1 and is incorporated herein by reference. The provisions of the Securities Purchase Agreement, including
the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreement or
as stated therein and are not intended as a document for investors and the public to obtain factual information about the current state
of affairs of the parties to the documents and agreements. Rather, investors and the public should look to other disclosures contained
in the Company&#8217;s filings with the Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 61.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02. Unregistered Sales of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
matters described in Item 1.01 of this Current Report on Form 8-K are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 58.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01. Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 7, 2025, the Company issued a press release announcing the Offering, which is furnished as Exhibit 99.1 hereto. The information
in Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 58.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement, dated August 4, 2025, by and between Processa Pharmaceuticals, Inc. and the Purchaser (as defined therein).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press release by Processa Pharmaceuticals, dated August 7, 2025.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized, on August 7, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCESSA
    PHARMACEUTICALS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Ng</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OWwVkvAxsYgsQiJ6XXKMJd2R2c3yk/rLNiUaBoaZe89cIWZiQ2vdIMNlVRZwwrZrlEMosUZGc0XvyLa7FPws8aatY2XcuP7AjDyDnknCSPn76Oy1xSoFuZzLZB4vQMaplHDci+CrZ2RqXaFxWjWgTAVHpo41OsXD9OGkXmSoHcakM7LVZFKIQjnJb4hlFMOBevUkvlsoikwEs7ECsWF6dN6VvxyaLwl5g62PsxP97+ADyIVKVw== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: right; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; text-transform: none"><B>Exhibit</B></FONT><B>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of August 4, 2025, between Processa Pharmaceuticals,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section
5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D promulgated thereunder, the Company desires to issue
and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company
as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed on a
day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Foley &amp; Lardner LLP, with offices located at 1 Independent Drive, Suite 1300, Jacksonville, FL 32202.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $0.23 (23 cents of US Dollars) subject to adjustment for reverse and forward stock splits, stock
dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares hereunder as specified below such Purchaser&rsquo;s
name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and
in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed
in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Continental Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 1 State Street, 30<SUP>th</SUP> Floor, New York, NY 10004 and an email address of sjones@continentalstock.com, and any successor
transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASE
AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $1,257,452 of Shares. Each Purchaser shall deliver to
the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser&rsquo;s Subscription Amount
as set forth on the signature page hereto executed by such Purchaser and the Company shall deliver to each Purchaser its respective Shares
as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable
at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices
of Company Counsel or such other location as the parties shall mutually agree.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
subject to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead
and executed by the Chief Executive Officer or Chief Financial Officer; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver the Shares
equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser
in book-entry form held at the Transfer Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a
specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS
AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby makes the following
representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All Subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly, all
of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them
in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business or financial condition of the Company and the
Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect
on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;)
and, to the Company&rsquo;s knowledge, no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or
seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as would not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) application(s) to each applicable Trading Market for the listing of the Shares
for trading thereon in the time and manner required thereby, and (iii) the filing of Form D with the Commission and such filings as are
required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth in the SEC Reports. Except as set forth
in the SEC Reports, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act,
other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of
Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there
are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for
or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents
or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue
shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments
of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or
instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the
Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of
any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder,
the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared, in all material respects, in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result
in a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required
to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)
the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock
and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock
option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for
the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries
or their respective businesses, properties, operations, assets or financial condition that would be required to be disclosed by the Company
under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least
1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). There are no Actions that (i) adversely affects or challenges the legality, validity
or enforceability of any of the Transaction Documents or the Securities or (ii) would, if there were an unfavorable decision, have or
reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof,
is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation
by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any
stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the
Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or
any restrictive covenant in favor of any third party, and to the Company&rsquo;s knowledge the continued employment of each such executive
officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company
and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages and hours, except where the failure to be in material compliance would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance, in all material respects, with all federal, state,
local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water,
groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of
chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental
Laws</U>&rdquo;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to
conduct their respective businesses as currently conducted; and (iii) are in compliance with all terms and conditions of any such permit,
license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually
or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except
for matters which are not expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all material patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC
Reports and which the failure to so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the
date of this Agreement. except for matters which are not expected to result in a Material Adverse Effect. Neither the Company nor any
Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice
of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except
as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing material infringement by another Person of any of the Intellectual Property
Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of
all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant
increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002, as amended that are effective as of the date hereof, and any and all applicable rules
and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company
and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the
Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the
Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the
disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed
periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal
control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. No brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company or any Subsidiary to any
broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions
contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims
made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions
contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. Except as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to
effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. Except as set forth on <U>Schedule 3.1(w)</U>, the Company is, and
has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance
requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established
clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or would become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes material, non-public information. The Company understands and confirms that
the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and
the transactions contemplated hereby is true and correct and does not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect
to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, and (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital
requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof.
The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from
the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s accounting firm is currently Cherry Bekaert LLP. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<FONT STYLE="text-decoration: underline solid">Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</FONT>. Anything in this Agreement
or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(e) and 4.14 hereof), it is understood and acknowledged by
the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing
or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company
or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically
including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private
placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser,
and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently
may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with
or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands and
acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities
are outstanding, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo; equity interests
in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned
hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Cybersecurity</U>. To the Company&rsquo;s knowledge (i)(x) there has been no security breach or other compromise of or relating to
any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data
(including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of
it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not
been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach
or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such
IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate,
have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards
as the Company believes to be appropriate for a Company of its size to maintain and protect its material confidential information and
the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have
implemented backup and disaster recovery technology consistent with industry standards and practices as considered reasonably necessary
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last year were, in compliance
in all material respects with all applicable state, federal and foreign data privacy and security laws and regulations, including, without
limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice
of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and
(iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its
subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy
Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph,
social security number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally
identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR;
and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy
Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any
court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities. Such
Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Validity</U>. The execution and delivery of the Transaction Documents to which such Purchaser is a party and the consummation by it
of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary action on the part of such
Purchaser and no further consent or authorization of such Purchaser or its members (or shareholders) is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>General Solicitation</U>. Such Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other communication
regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any
seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER
AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Transfer Restrictions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Shares
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion
of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the
Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and
shall have the rights and obligations of a Purchaser under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Shares in the following
form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THESE
SHARES OF COMMON STOCK HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Shares to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer
pledged or secured the Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the
Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further,
no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable
documentation as a pledgee or secured party of the Securities may reasonably request in connection with a pledge or transfer of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Certificates evidencing the Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof), (i) while
a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such
Shares pursuant to Rule 144, (iii) if such Shares are eligible for sale under Rule 144, without the requirement for the Company to be
in compliance with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions,
or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser
promptly after the Effective Date if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by
a Purchaser, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Shares
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or
an exemption therefrom, and that if Securities are sold pursuant to a registration statement, they will be sold in compliance with the
plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Shares
as set forth in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>. Until the earliest of the time that no Purchaser owns Securities, the Company covenants to use commercially
reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required
to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting
requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall issue a press release disclosing the material terms of the transactions
contemplated hereby and/or file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission
within the time required by the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser would be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material pricing terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing
to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To
the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates
delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and
agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, employees, Affiliates or agents, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, Affiliates or agents not to trade on the basis of, such material, non-public information, provided that the Purchaser
shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such
notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes
and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables
in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock
Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the
transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may
have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a
material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be
liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior
written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim,
damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or other
agreements in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by
periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred.
The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against
the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation
of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply
to list or quote all of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted
on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing
and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other
obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic
transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment
of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered
to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser
by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed
to its legal and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the
contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be
restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws
from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates, or agent
after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on
the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by
the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately
and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted Purchaser (or at least 50.1%
in interest of such multiple Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely
affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require
the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding
upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the State of Florida. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the State of Florida for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition
to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the
convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood
and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser,
solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PROCESSA
    PHARMACEUTICALS, INC. </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
                                            for Notice:</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 48%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy to (which shall not constitute notice):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGE TO <FONT STYLE="text-transform: uppercase">PCSA </FONT>SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: ___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Shares to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Processa
Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VERO
BEACH, Fla., August 07, 2025 (GLOBE NEWSWIRE) &mdash; Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), </B>a clinical-stage biopharmaceutical
company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment
and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that strategic engagement with emerging financial technologies, including select cryptocurrencies with potential yield-generating
capabilities, may offer novel avenues to diversify our capital base and enhance financial flexibility, while providing an opportunity
for long-term value creation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we remain committed to rigorous compliance with all applicable regulatory standards, we recognize the potential for blockchain-based
assets to contribute meaningfully to the funding of our clinical development programs. This approach could allow us to reduce dilution
for existing shareholders, access additional sources of capital, and position the company at the forefront of biotech-fintech convergence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are evaluating these opportunities with a focus on long-term value creation, transparency, and responsible stewardship of investor capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
Ng, CEO of Processa stated, &ldquo;We continue to deliver on the operational commitments, seeking meaningful therapies for
patients, while exploring innovative financial strategies that can support optimal outcomes for Processa&rsquo;s shareholders and
stakeholders.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
has also engaged LifeSci Capital, LLC in an advisory capacity in connection with implementing its cryptocurrency treasury strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Processa Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy.
Processa&rsquo;s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism
and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology
pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa&rsquo;s strategy is to develop more
effective therapy options with improved tolerability for cancer patients through an efficient regulatory path. In addition to its core
oncology programs, Processa is actively pursuing strategic partnerships for non-oncology assets to unlock additional value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, visit our website at <U>www.processapharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking
statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed
in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained
in the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
Lin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(925)
683-3218</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>plin@processapharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
Gentry</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip
Companies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-407-644-4256</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PCSA@redchip.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pcsa-20250804.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaiHibP9z5Z8uekhvWB7bflKnyUsekhpUSKD63EmUYwE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:PCSA="http://processapharmaceuticals.com/20250804" elementFormDefault="qualified" targetNamespace="http://processapharmaceuticals.com/20250804">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pcsa-20250804_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pcsa-20250804_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250804.xsd#Cover" roleURI="http://processapharmaceuticals.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROCESSA
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1539785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601
21st Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vero
Beach<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">32960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">453-2899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock: Par value $.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCSA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>pcsa-20250804.xsd</File>
    <File>pcsa-20250804_lab.xml</File>
    <File>pcsa-20250804_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "PCSA",
   "nsuri": "http://processapharmaceuticals.com/20250804",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "pcsa-20250804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pcsa-20250804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcsa-20250804_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://processapharmaceuticals.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001493152-25-011680-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-011680-xbrl.zip
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M/CY(X)%YUKIYDC5)M4B.-Q<P@N1)FCQZ^.AIFDQ=>^5<F;RKJYEKFBQYM\Q
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MH/.6AB.UR&?P;O)1HC'0)D?)*^CWVE'GDQ<U;9.S#6@#R='CAP_3Y'^#W=_
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MG]>UNZRX:(_=3'JW>9<9.=G"(U)RIO-UMZJ.F :_PK9).$/?[]=W3M!!'?:
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M8,W-$WX+$)61H,22*67FF.Z>'%A!7@_4XB-9<HMB?,F$-PEYL>. W0F/E9B
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MR+8ENU/VYT\<P;W;K'^L,W@;7_+CO2_Y\WW)C_>^Y&_YG'VYN^[2YW@&'M$
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MMT0^A18FK'8@/DHJPA$X[^9N5DBFG2E\(.7"H[/4J< DB$M.\>,X,MUX5*8
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MFT.*EA)#.U2,)\EA"B5O6(8.+<QV!OU9\R^V#ZCBT=RLS3/E#HPFB.,P9":
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MKZKG0*M"P",;LH^9&5!_FJA.?;]-3-4LA4R9G5FAI\FU'67T4AT%FW$SR$8
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MM<1>SUB;I<5:<)9W)CF9"'2&F2XXE\F7:B%XB6.=%OG*F2HAW&=F@G:4-2
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M*0/I(X8Z\7NP%4?$=>R.[48XNWF[2#*BR9!SWP[ZTK>=W_)=E3>4V%CBK3A
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MDC P3693^$PV+.$'R,D_;&:')")N--%YUXSR7H_YU-*@=@Q9@L34:79R!X%
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MW,H_-@X9A*3394MU?SUMMQI_2,L1E"E=KGP7GV(<M2_E07E$Y_5/YIE0^=T
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M\QY<^2699-C_<OXUU_!!CS.+2,)9Y$Q3;7P)RV:Y\KRS5%1O7E\C$*2IK9
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MC?-J\B5ATOWS(7[+62"".K9Y0!Z0(7E-&9#;1LA+1E48(3OU*5AI#,V32 ?
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M$],:DF+B"^EQ'17&!>%XF$UC&K%-(OC0T6UJ,-,1^HP(".5%;R9K>A7,+K!
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MS+\(YL-P:2C]P&)8M:-2RP($1??6AXG4>X%DMN6\Y1J><6"ILYNR/6;K^[.
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M\0L0>*@"->KXT)BQ?%[,DP^-RVQN+'I:/&)Q &^W>29G4&$,O@K>&>3X]L*
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M,2YH=&U02P$"% ,4    " ##0P=;:/8.O*47  #^J0  "P
M@ %VCP  9F]R;3@M:RYH=&U02P$"% ,4    " ##0P=;PIP%9#$#   /#
M$0              @ %$IP  <&-S82TR,#(U,#@P-"YX<V102P$"% ,4
M" ##0P=;71??Y_T*  !_A@  %0              @ &DJ@  <&-S82TR,#(U
M,#@P-%]L86(N>&UL4$L! A0#%     @ PT,'6Z=%MPQF!P  \E<  !4
M         ( !U+4  '!C<V$M,C R-3 X,#1?<')E+GAM;%!+!08     !@ &
+ &X!  !MO0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pcsa-20250804.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-04" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-04" id="Fact000004">0001533743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-04" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-04" id="Fact000010">2025-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="AsOf2025-08-04" id="Fact000011">001-39531</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-04" id="Fact000012">PROCESSA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-04" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-04" id="Fact000014">45-1539785</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-04" id="Fact000015">601 21st Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-08-04" id="Fact000016">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-04" id="Fact000017">Vero Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-04" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-04" id="Fact000019">32960</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-04" id="Fact000020">(772)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-04" id="Fact000021">453-2899</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-04" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-04" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-04" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-04" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-08-04" id="Fact000026">Common     stock: Par value $.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-08-04" id="Fact000027">PCSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-08-04" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-04" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
